Having trouble accessing articles? Reset your cache.

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen to evaluate Pfizer asset to normalize circadian rhythm-associated Alzheimer’s, Parkinson’s symptoms

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease.

Monday’s deal is Biogen’s

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE